The content on this site is intended for healthcare professionals only
Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) and Dr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium) discuss the recommendations from the EBCC 2024 manifesto session.
The manifesto session's main aim was to address inequalities across Europe in access to innovation for patients with metastatic breast cancer.
The manifesto was divided into four categories: stigma, registries and real-world data, multidisciplinary care, and quality indicators.
The panellists highlight the seven recommendations from this session.
Low-dose pembrolizumab plus neoadjuvant chemo option for TNBC in resource-constrained settings
Transforming cancer care in India: The Access Cancer Care Initiative
Burden and trends of breast cancer worldwide: Opportunities for prevention?
Key insights from lung cancer research at ASCO 2025
Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours
Breast and emerging indications for IORT
The advantages of IORT for early breast cancer treatment
The role of CDK4/6 inhibitors in the treatment of metastatic breast cancer
Neo-adjuvant therapy for different cancers in the Philippines
